Alendronate 복용으로 유발된 위궤양 1 예
Alendronate (Fosamax), an aminobisphosphonate and a selective inhibitor of osteoclast-mediated bone resorption, is used to treat postmenopausal osteoporosis and Paget's disease. In recent years, reports of severe esophageal injury in patients who took alendronate have evoked attention to the ir...
Gespeichert in:
Veröffentlicht in: | The Korean journal of gastroenterology 2001-11, Vol.38 (4), p.284 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | kor |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Alendronate (Fosamax), an aminobisphosphonate and a selective inhibitor of osteoclast-mediated bone resorption, is used to treat postmenopausal osteoporosis and Paget's disease. In recent years, reports of severe esophageal injury in patients who took alendronate have evoked attention to the irritant effects of this drug on the mucosa of the upper gastrointestinal tract. We present a case of gastric ulcer caused by alendronate. The patient chiefly complainted of epigastric pain during 14 days. She had taken mefenamic acid for pain control for 3 years and she took once-weekly 70 mg of alendronate for 2 weeks for treatment of osteoporosis before the symptom started. Upper gastrointestinal endoscopy revealed two active gastric ulcers in the low body. The results of rapid urease test (CLO test) and modified Giemsa test for the detection of Helicobacter pylori infection were negative. After withdrawal of alendronate, the symptom resolved completely in one week. Six weeks later, follow-up endoscopy showed complete healing of the ulcer. (Korean J Gastroenterol 2001;38:284-287) |
---|---|
ISSN: | 1598-9992 |